DBV Technologies (NASDAQ:DBVT) Given “Market Outperform” Rating at JMP Securities

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating restated by JMP Securities in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock. JMP Securities’ price objective points to a potential upside of 203.95% from the stock’s current price.

A number of other analysts have also issued reports on DBVT. HC Wainwright increased their target price on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th. StockNews.com started coverage on DBV Technologies in a research note on Sunday. They issued a “hold” rating for the company.

DBV Technologies Trading Down 4.6 %

DBVT stock opened at $3.29 on Tuesday. The firm has a 50-day moving average of $3.45 and a two-hundred day moving average of $4.04. The firm has a market capitalization of $67.68 million, a PE ratio of -0.73 and a beta of 0.64. DBV Technologies has a one year low of $2.20 and a one year high of $10.70.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.